indicates material omitted and filed separately with the Securities and Exchange Commission Pursuant to a request for confidential treatment.] second installment of ***************************** due no later than April 1, **** and a Third Installment...Exclusive License Agreement • March 31st, 2000 • V I Technologies Inc • Biological products, (no disgnostic substances)
EXHIBIT 10.14 -------------Omnibus Agreement • March 31st, 2000 • V I Technologies Inc • Biological products, (no disgnostic substances)
EXHIBIT 10.11 FIRST AMENDMENT TO APPENDIX A OF THE LICENSE AGREEMENTS BETWEEN THE NEW YORK BLOOD CENTER, INC. AND MELVILLE BIOLOGICS, INC. (NOW V.I. TECHNOLOGIES, INC., OR VITEX) This First Appendix A Amendment, effective January 1, 1999, is made and...License Agreement • March 31st, 2000 • V I Technologies Inc • Biological products, (no disgnostic substances)
V VITEX February 16, 2000 By Facsimile and Certified Mail Mark DeWyngaert Director, Office of Patents & Licenses Commercial Development The New York Blood Center, Inc. 310 E. 67th Street New York, NY 10021-6295 Re: Exclusive License Agreement (#5) for...Exclusive License Agreement • March 31st, 2000 • V I Technologies Inc • Biological products, (no disgnostic substances)
